Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Thorax

• Publication date

  2006-06-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/thx.2005.057950PMID 16809416PMCID PMC2104771
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cystic Fibrosis

  2009cited by this paper
• Cystic fibrosis pulmonary exacerbations.

  2006cited by this paper
• Competing interests: none declared.

  2006cited by this paper
• Cystic fibrosis, pediatrics, control of breathing, pulmonary physiology and anatomy, and surfactant biology in AJRCCM in 2004.

  2005cited by this paper
• Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

  2005cited by this paper
• Age-Related Prevalence and Distribution of Nontuberculous Mycobacterial Species among Patients with Cystic Fibrosis

  2005cited by this paper
• Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971].

  2005cited by this paper
• Azithromycin in cystic fibrosis

  2005cited by this paper
• Low-dose, long-term macrolide therapy in asthma: An overview

  2004cited by this paper
• Pulmonary exacerbations in cystic fibrosis

  2004cited by this paper
• Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!

  2004cited by this paper
• Azithromycin for cystic fibrosis

  2004cited by this paper
• Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa.

  2004cited by this paper
• Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection.

  2004cited by this paper
• Analysis of Longitudinal Data (2nd ed.) (Book)

  2004cited by this paper
• Analysis of Longitudinal Data(second edition) Diggle P, Heagarty P, Liang K-Y, Zeger S(2002)ISBN 0198524846; 396 pages;£40.00,$85.00 Oxford University Press;

  2004cited by this paper
• Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

  2003cited by this paper
• Cystic fibrosis

  2003cited by this paper
• Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases.

  2003cited by this paper
• Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients

  2003cited by this paper
• Analysis of Longitudinal Data

  2003cited by this paper
• Annual lung function changes in young patients with chronic lung disease

  2002cited by this paper
• Monitoring inflammation in CF

  2002cited by this paper
• Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

  2002cited by this paper
• Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial

  2002cited by this paper
• Cystic fibrosis

  2001cited by this paper
• Anti‐inflammatory effects of macrolides in lung disease *

  2001cited by this paper
• Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: A pilot study *

  2001cited by this paper
• Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction.

  2001cited by this paper
• Modern statistical techniques for the analysis of longitudinal data in biomedical research

  2000cited by this paper
• The genesis of cystic fibrosis lung disease.

  1999cited by this paper
• Long-term azithromycin may improve lung function in children with cystic fibrosis.

  1998cited by this paper
• Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis.

  1997cited by this paper
• Identifying Treatments That Halt Progression of Pulmonary Disease in Cystic Fibrosis

  1997cited by this paper
• Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy.

  1996cited by this paper
• Body Mass Index variations: centiles from birth to 87 years.

  1991cited by this paper
• Changes in the normal maximal expiratory flow-volume curve with growth and aging.

  1983cited by this paper
• The genesis of cystic fibrosis lung disease

  year unknowncited by this paper

• Prophylactic antibiotics in chronic pediatric lung disease: balancing benefit, resistance, and future care models.

  2026cites this paper
• Effects of azithromycin in young adults with cystic fibrosis: a protocol for emulating a published randomised controlled trial using registry data

  2025cites this paper
• In Vitro Analysis of Azithromycin's Effect on J774 Murine Macrophages Challenged with Aspergillus fumigatus: Azithromycin Improves Macrophage Response to Aspergillus fumigatus.

  2025cites this paper
• The Impact of Azithromycin on Lung Function in Children And Adolescents with Cystic Fibrosis: A Systematic Review And Meta-Analysis.

  2025cites this paper
• Efficacy of Long-Term Use of Azithromycin in the Management of Cystic Fibrosis in Pediatric Patients with or Without Pseudomonas aeruginosa: A Systematic Review and Meta-Analysis Article

  2025cites this paper
• Systematic development and optimization of a microfluidic formulation protocol for liposomal azithromycin

  2025cites this paper
• Examining the safety and efficacy of Azithromycin in Cystic fibrosis: A systematic review and Meta-analysis.

  2025cites this paper
• Long-term Azithromycin Prophylaxis in Pediatric Respiratory Disorders: A Narrative Review and Applications in Hong Kong

  2025cites this paper
• The effect of azithromycin treatment on respiratory morbidity in children with down syndrome

  2025cites this paper
• Azithromycin Augments Bacterial Uptake and Anti-Inflammatory Macrophage Polarization in Cystic Fibrosis

  2024cites this paper
• Therapeutic Interventions for Pseudomonas Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials

  2024cites this paper
• Reversible deafness related to long‐term daily Azithromycin treatment in a child with cystic fibrosis

  2024cites this paper
• Macrolide antibiotics (including azithromycin) for cystic fibrosis.

  2024cites this paper
• Long‐Term Safety Profiles of Macrolides and Tetracyclines: A Systematic Review and Meta‐Analysis

  2023cites this paper
• A protocol for emulating a published randomised controlled trial using registry data: effects of azithromycin in young adults with cystic fibrosis

  2023cites this paper
• Overcoming Native Macrolide and Acquired Multidrug-Resistant Pseudomonas aeruginosa with Azithromycin and Polymyxin B Nonapeptide

  2023cites this paper
• Mechanism of action, resistance, synergism, and clinical implications of azithromycin

  2022cites this paper
• Pleiotropic effects of antibiotics on T cell metabolism and T cell-mediated immunity

  2022cites this paper
• The Efficacy and Safety of Azithromycin for Patients with Cystic Fibrosis: A Systematic Review

  2022cites this paper
• Optimization and Characterization of a Liposomal Azithromycin Formulation for Alternative Macrophage Activation

  2022cites this paper
• Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections.

  2022cites this paper
• The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.

  2022cites this paper
• Novel Immunomodulatory Therapies for Respiratory Pathologies

  2022cites this paper
• Nontuberculous Mycobacterial Infections in Cystic Fibrosis.

  2022cites this paper
• The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies

  2022cites this paper
• Investigation of Growth of Microorganisms within the Spacers of Children with Cystic Fibrosis

  2022cites this paper
• A case report of inherited surfactant protein deficiency: unknown cause of diffuse infiltrative diseases in Tunisia

  2022cites this paper
• Delivering macrolide antibiotics to heal a broken heart - and other inflammatory conditions.

  2022cites this paper
• Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development

  2021cites this paper
• The Gut-Lung Axis in Cystic Fibrosis

  2021cites this paper
• Prognosis and treatment of 46 Chinese pediatric cystic fibrosis patients

  2021cites this paper
• Study protocol for a randomised controlled trial evaluating the clinical effect of antibiotic prophylaxis in children with recurrent respiratory tract infections: the Approach study

  2021cites this paper
• Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases

  2021cites this paper
• Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19

  2021cites this paper
• Clarithromycin impairs tissue-resident memory and Th17 responses to macrolide-resistant Streptococcus pneumoniae infections

  2021cites this paper
• Azithromycin and the microbiota of cystic fibrosis sputum

  2021cites this paper
• Azithromycin Exhibits Activity Against Pseudomonas aeruginosa in Chronic Rat Lung Infection Model

  2021cites this paper
• Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review

  2021cites this paper
• Nontuberculous Mycobacterium

  2020cites this paper
• Azithromycin is the answer in paediatric respiratory medicine, but what was the question?

  2020cites this paper
• Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis

  2020cites this paper
• Cystic Fibrosis: A Multi-Organ System Approach

  2020influential citation
• Quantifying Long-term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis.

  2020cites this paper
• Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.

  2020cites this paper
• Effects of a sub-minimum inhibitory concentration of chlorhexidine gluconate on the development of in vitro multi-species biofilms

  2020cites this paper
• Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells

  2020cites this paper
• Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies

  2020cites this paper
• Anti-Bacterial vs. Anti-Biofilm Effects of Azithromycin on Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

  2020cites this paper
• LC-MS detection of antibiotic agents in sputum from persons with cystic fibrosis.

  2020cites this paper
• Azithromycin for chronic eosinophilic rhinosinusitis with nasal polyp: a placebo-controlled trial.

  2020cites this paper
• Use of Antibiotics in Chronic Obstructive Pulmonary Disease: What is Their Current Role in Older Patients?

  2020cites this paper
• Nontuberculous Mycobacterial Infections in Cystic Fibrosis.

  2019cites this paper
• Nontuberculosis Mycobacterial Disease

  2019cites this paper
• Evaluating Long-Term Benefits of Chronic Azithromycin. Furthering Our Quest for Precision Medicine

  2019cites this paper
• Towards evidence-based medicine for paediatricians

  2019cites this paper
• Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations.

  2019cites this paper
• Targeting airway inflammation in cystic fibrosis

  2019cites this paper
• Macrolides, Reflux and Respiratory Disease

  2018cites this paper
• Inflammation in cystic fibrosis: An update

  2018cites this paper
• The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms

  2018cites this paper
• Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment‐Emergent Respiratory Pathogens

  2018cites this paper
• Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa.

  2018cites this paper
• Chimera Ligand for Pili and Lectin A Protein Controls Antibiotic-Promoted Biofilm Formation, Swarming Motility, Tolerance and Persister Formation by Pseudomonas aeruginosa

  2018cites this paper
• Genetic mutations of Cystic Fibrosis disease in North West in Iran based on Registry Center of Cystic Fibrosis

  2018cites this paper
• ALTERNATIVELY ACTIVATED MACROPHAGES IN PSEUDOMONAS AERUGINOSA PNEUMONIA: MODULATION OF THE NF-ΚB SIGNALING PATHWAY AND THE IMMUNOMODULATORY ROLE OF ARGINASE-1

  2018influential citation
• Microbiota manipulation for weight change.

  2017cites this paper
• Macrolide maintenance treatment for bronchiectasis

  2017cites this paper
• Brazilian guidelines for the diagnosis and treatment of cystic fibrosis

  2017cites this paper
• Diretrizes brasileiras de diagnóstico e tratamento da fibrose cística

  2017cites this paper
• The Effects of Long-term Macrolide Therapy in COPD Patients with Frequent Exacerbations

  2017cites this paper
• Long-term oral antibiotic treatment : why, what, when and to whom?

  2017influential citation
• Cystic Fibrosis: An Overview of the Past, Present, and the Future

  2017cites this paper
• Limitations and Adverse Influences of Antimicrobial Strategy for the Control of Oral Biofilm

  2017cites this paper
• MACROLIDES PROTECT AGAINST PSEUDOMONAS AERUGINOSA INFECTION VIA INHIBITION OF INFLAMMASOMES

  2017cites this paper
• The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis.

  2017cites this paper
• The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis

  2017cites this paper
• Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma

  2017cites this paper
• Azithromycin for the treatment of eosinophilic nasal polyposis: Clinical and histologic analysis

  2016cites this paper
• Question 5: What is the role of macrolide antibiotics as anti-inflammatory treatment in Cystic fibrosis?

  2016cites this paper
• Adverse Influences of Antimicrobial Strategy against Mature Oral Biofilm

  2016cites this paper
• Respiratory manifestations and management in children with Common Variable Immunodeficiency.

  2016cites this paper
• Cystic Fibrosis Sinusitis.

  2016cites this paper
• The solithromycin journey-It is all in the chemistry.

  2016cites this paper
• Amoxicillin for the secondary prevention of rheumatic fever in children not allergic to penicillin

  2016cites this paper
• Long-term effects of azithromycin in patients with cystic fibrosis.

  2016cites this paper
• Solithromycin Diminishes Steatohepatitis by Modulating Gluconeogenesis and Inhibits Tumor Growth in a Diabetic Mouse Model of Non-Alcoholic Steatohepatitis

  2016cites this paper
• Immunomodulatory effects of macrolide antibiotics – part 2: advantages and disadvantage of macrolide maintenance therapy

  2016cites this paper
• Long term azithromycin therapy in patients with cystic fibrosis.

  2016cites this paper
• Azithromycin use in patients with cystic fibrosis

  2015cites this paper
• [National consensus regarding azithromycin use in cystic fibrosis].

  2015cites this paper
• Adverse events in people taking macrolide antibiotics versus placebo for any indication.

  2015cites this paper
• The road for survival improvement of cystic fibrosis patients in Arab countries

  2015cites this paper
• Nontuberculous Mycobacterial Infections in Cystic Fibrosis.

  2015cites this paper
• Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.

  2015cites this paper
• The role of emerging pathogens in adults with cystic fibrosis

  2015cites this paper
• Prophylactic Use of Macrolide Antibiotics for the Prevention of Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis

  2015cites this paper
• Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under.

  2015cites this paper
• The effects of azithromycin on cell signalling in human bronchial epithelium

  2015cites this paper
• Cystic fibrosis

  2015cites this paper
• Infection, inflammation & innate immunity in the paediatric CF airway

  2015cites this paper